Spectroscopic Assessment of Tissue Oxygenation Changes During Vascular Surgery
1 other identifier
observational
30
0 countries
N/A
Brief Summary
This study is a single-center, observational study designed to collect tissue spectrometric data related to tissue oxygenation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Dec 2026
Longer than P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 20, 2026
CompletedFirst Posted
Study publicly available on registry
August 26, 2026
CompletedStudy Start
First participant enrolled
December 1, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2027
Study Completion
Last participant's last visit for all outcomes
July 31, 2031
August 26, 2026
August 1, 2026
1.1 years
August 20, 2026
August 25, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Observe changes in skeletal muscle tissue oxygenation
To observe the changes in skeletal muscle tissue oxygenation (combined hemoglobin/myoglobin saturation, %) measured by the SpectroCor Monitoring System during arterial clamping and restoration of limb perfusion. Continuous spectroscopic measurement of combined hemoglobin and myoglobin oxygen saturation in skeletal muscle of the operated limb, recorded from a SpectroCor Sensor placed in the distal wound before any arterial clamping. Saturation values are time-stamped against intraoperative events affecting limb perfusion (proximal arterial clamping, unclamping, graft revision) and compared with paired arterial and venous blood gas samples obtained before clamping and after restoration of blood flow.
From sensor placement prior to arterial clamping until restoration of limb blood circulation and completion of vascular reconstruction quality control (intraoperative period, approximately 2-6 hours)
Secondary Outcomes (1)
Incidence of adverse events, adverse device effects, and device deficiencies
From sensor placement during the operation until discharge from hospital (up to 30 days)
Eligibility Criteria
A Helsinki University Hospital patient scheduled for a vascular surgical operation.
You may qualify if:
- Adults, age of 18 - 90 years
- Scheduled for peripheral arterial bypass surgery.
- Scheduled for proximal arterial reconstruction.
- Ability and willingness to provide informed consent.
You may not qualify if:
- Inability to provide informed consent
- Considered a vulnerable person according to the Finnish Medical Research Act (488/1999), Chapter 2, Sections 7, 9, and 10, including retarded persons, pregnant women, nursing mothers, prisoners, and forensic patients.
- A known history of severe allergic reaction to nickel.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Spectrocorlead
- Helsinki University Central Hospitalcollaborator
Related Publications (9)
Keller A. Noninvasive tissue oximetry for flap monitoring: an initial study. J Reconstr Microsurg. 2007 May;23(4):189-97. doi: 10.1055/s-2007-974655.
PMID: 17530610BACKGROUNDKeller A. A new diagnostic algorithm for early prediction of vascular compromise in 208 microsurgical flaps using tissue oxygen saturation measurements. Ann Plast Surg. 2009 May;62(5):538-43. doi: 10.1097/SAP.0b013e3181a47ce8.
PMID: 19387157BACKGROUNDSteele MH. Three-year experience using near infrared spectroscopy tissue oximetry monitoring of free tissue transfers. Ann Plast Surg. 2011 May;66(5):540-5. doi: 10.1097/SAP.0b013e31820909f9.
PMID: 21301288BACKGROUNDChen Y, Shen Z, Shao Z, Yu P, Wu J. Free Flap Monitoring Using Near-Infrared Spectroscopy: A Systemic Review. Ann Plast Surg. 2016 May;76(5):590-7. doi: 10.1097/SAP.0000000000000430.
PMID: 25664408BACKGROUNDTran PC, DeBrock W, Lester ME, Hartman BC, Socas J, Hassanein AH. The False Positive Rate of Transcutaneous Tissue Oximetry Alarms in Microvascular Breast Reconstruction Rises after 24 Hours. J Reconstr Microsurg. 2021 Jun;37(5):453-557. doi: 10.1055/s-0040-1719048. Epub 2020 Oct 31.
PMID: 33129214BACKGROUNDAli J, Cody J, Maldonado Y, Ramakrishna H. Near-Infrared Spectroscopy (NIRS) for Cerebral and Tissue Oximetry: Analysis of Evolving Applications. J Cardiothorac Vasc Anesth. 2022 Aug;36(8 Pt A):2758-2766. doi: 10.1053/j.jvca.2021.07.015. Epub 2021 Jul 10.
PMID: 34362641BACKGROUNDSchanzer A, Hevelone N, Owens CD, Belkin M, Bandyk DF, Clowes AW, Moneta GL, Conte MS. Technical factors affecting autogenous vein graft failure: observations from a large multicenter trial. J Vasc Surg. 2007 Dec;46(6):1180-90; discussion 1190. doi: 10.1016/j.jvs.2007.08.033.
PMID: 18154993BACKGROUNDEiberg JP, Schroeder TV, Vogt KC, Secher NH. Near-infrared spectroscopy during peripheral vascular surgery. Cardiovasc Surg. 1997 Jun;5(3):304-8. doi: 10.1177/096721099700500309.
PMID: 9293366BACKGROUNDDubosq M, Goueffic Y, Duhamel A, Denies F, Dervaux B, Goyault G, Sobocinski J. Optical Coherence Tomography Contribution Assessment in the Revascularization of Long Femoropopliteal Occlusive Lesions (TASC C and D): A Randomized Trial. Ann Vasc Surg. 2021 Jan;70:362-369. doi: 10.1016/j.avsg.2020.06.061. Epub 2020 Jul 4.
PMID: 32634565BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Maarit Venermo, Professor
Helsinki University Hospital (HUS)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 20, 2026
First Posted
August 26, 2026
Study Start (Estimated)
December 1, 2026
Primary Completion (Estimated)
December 31, 2027
Study Completion (Estimated)
July 31, 2031
Last Updated
August 26, 2026
Record last verified: 2026-08
Data Sharing
- IPD Sharing
- Will not share
Individual participant data will not be shared. Participant consent and the approved Clinical Investigation Plan do not cover secondary sharing of individual-level data, and the sponsor's obligations under Regulation (EU) 2016/679 (GDPR) preclude onward transfer without a valid legal basis. Aggregate results will be published in accordance with the publication policy and made publicly available in EUDAMED, and the clinical investigation report will be submitted to the competent authority within one year of the end of the investigation.